Skip to search formSkip to main contentSkip to account menu
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
TLDR
New consensus criteria for eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone are defined, with increasing emphasis on time-to-event end points as decision aids in proceeding from phase II to phase III trials.
View on PubMed
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
TLDR
The purpose of determining the number of patients whose PSA level drops in a phase II trial of AIPC is to guide the selection of agents for further testing and phase III trials and developed practical guidelines for using PSA as a measurement of outcome.
View on PubMed
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients…
TLDR
IL-15 could be safely administered to patients with metastatic malignancy and markedly altered homeostasis of lymphocyte subsets in blood, with NK cells and γδ cells most dramatically affected, followed by CD8 memory T cells.
View on PubMed
Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo
TLDR
Nelfinavir is a lead HIV protease inhibitor with pleiotropic effects in cancer cells and is a Food and Drug Administration–approved drug that could be repositioned as a cancer therapeutic.
View on Publisher
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
TLDR
The histone deacetylase inhibitor romidepsin has single-agent clinical activity with significant and durable responses in patients with CTCL.
View on PubMed
Angiogenesis Inhibitors: Current Strategies and Future Prospects
TLDR
Key molecular mechanisms and novel therapies that are on the horizon for antiangiogenic tumor therapy are described.
View on Wiley
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
TLDR
Treatment with ubiquinone was associated with reversal of lovastatin-induced myopathy, and its prophylactic administration prevented the development of this toxicity in a cohort of 56 patients.
View on PubMed
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
TLDR
The histone deacetylase inhibitor romidepsin has single agent clinical activity associated with durable responses in patients with relapsed PTCL and supported the approval of romidepsypsin for CTCL.
View on PubMed
Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review
TLDR
This review is an effort to summarize the nonclinical and clinical status of HDAC inhibitors currently under development in anticancer therapy.
View on Publisher
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License